Written and maintained by CASRAI Editorial Board
Published
On this page
The FDA CLIA Database is a public search tool, run by FDA’s Center for Devices and Radiological Health (CDRH), that lists in vitro diagnostic test systems with their CLIA complexity category: waived, moderate or high. It lists tests, not laboratories. The FDA does not certify labs, and a laboratory’s CLIA certificate and certification status sit with the Centers for Medicare and Medicaid Services (CMS) and the State Survey Agencies instead. As described on the official pages on 2026-11-19, the FDA database answers “how complex is this test?”, while the CMS lookup answers “is this laboratory certified?”.
This page is for laboratory managers, compliance staff and research administrators who need to know which of the two tools to open, how to use the FDA one, and what the category it returns means for the laboratory that runs the test. For the certificate side, see our guides on CLIA certification and looking up a CLIA number.
What the FDA CLIA Database is and who runs it
Under the Clinical Laboratory Improvement Amendments (CLIA), the complexity of a test determines the standards a laboratory must meet to run it. The CDC describes the division of work among three agencies: CMS publishes the regulations, the waived-test list and the list of provider-performed microscopy procedures and decides which states are CLIA-exempt; the FDA scores commercially available cleared or approved tests during premarket review, handles waiver applications and maintains searchable databases; the CDC works with both. The FDA page on CLIA categorizations states that within FDA the categorization is conducted by CDRH.
The database is public and, according to the FDA, is updated weekly with new categorizations. Each categorization is effective from the date of the written notification the FDA sends to the manufacturer, so a test can be categorized before it reaches the weekly list. The tool is published on the FDA’s accessdata site as the CLIA Database search page.
Who the database is for and what it lists
Nothing on the official pages restricts who may search; it is open to laboratories, manufacturers, buyers and researchers. What it contains is a record per categorized test system, searchable by manufacturer, analyte, document number, complexity and several other fields described below. It does not contain a laboratory’s name, address, CLIA number or certificate type, so searching it for a lab will return nothing useful. That mismatch is the most common reason people struggle with this query: several lookup pages and APIs that rank for “CLIA database” are about laboratory demographic data, which is the CMS side.
How to search the FDA CLIA Database, field by field
The search page offers these fields, as described on the official page on 2026-11-19:
- Test System / Manufacturer: a single word or an exact phrase. The search is not case sensitive, but too many words or a misspelling may return nothing, so start with the manufacturer name or one distinctive word.
- Analyte Name: chosen from a dropdown, useful when you know what is measured but not who makes the test.
- Document Number: the identifier of the FDA record, such as a CLIA Record number.
- Complexity: High, Moderate or Waived.
- Analyte Specialty: for example bacteriology, hematology, toxicology/therapeutic drug monitoring or virology.
- 510(k) Exempt: yes or no.
- Effective Date: a from-to range, handy for finding what was added recently.
Results can be sorted by effective date, test system name, analyte name or document number, and the page links to a “Learn More” explanation and to downloadable files. A practical pattern: filter by complexity and analyte specialty first, then narrow by manufacturer. When a test you expect is missing, check whether the manufacturer’s marketing submission is listed in the FDA 510(k) database.
How a test system gets into the database
The FDA tracks categorizations through CLIA Record (CR) submissions. A CR number begins with “CR” followed by six digits: the first two are the year and the last four the submission number for that year.
- Concurrent CR: created automatically when CDRH receives an in vitro diagnostic marketing submission (510(k), De Novo, PMA or HDE).
- Standalone CR: created on request for legally marketed test systems that do not need a new marketing submission, for example name changes, new reagent-instrument combinations under the FDA’s replacement reagent and instrument family policy, and 510(k)-exempt tests.
- CLIA Waiver by Application (CW): a separate request. After the initial categorization, the manufacturer of a test categorized as moderate complexity may ask for it to be categorized as waived. The FDA publishes CLIA waiver by application decision summaries.
The FDA states there is no MDUFA user fee for a CR. Once a CR is completed, it appears in the public database at the next weekly update.
How the complexity score works
For tests that are not waived, the FDA scores seven criteria, each from 1 (lowest complexity) to 3 (highest). A 2 is used when the test falls between the descriptions for 1 and 3.
| # | Criterion scored 1 to 3 |
|---|---|
| 1 | Knowledge |
| 2 | Training and experience |
| 3 | Reagents and materials preparation |
| 4 | Characteristics of operational steps |
| 5 | Calibration, quality control and proficiency testing materials |
| 6 | Test system troubleshooting and equipment maintenance |
| 7 | Interpretation and judgment |
A total of 12 or less is moderate complexity; a total above 12 is high complexity. Waived tests are those waived under 42 CFR 493.15(c) or cleared or approved for home use. A test system that has not been categorized defaults to high complexity under 42 CFR 493.17 until it is categorized, and the CDC adds that laboratory-developed or modified tests default to high complexity as well. A worked reading: a test that scores 2 on all seven criteria totals 14 and is high complexity, while the same test with a 1 on two criteria totals 12 and is moderate. This arithmetic follows the FDA’s stated rule; it is not an FDA example.
What the category means for the laboratory
The category in the database tells a laboratory what compliance track the test falls under. According to the CDC and CMS pages as described on 2026-11-19:
- Waived: the laboratory needs a CLIA certificate and follows the manufacturer’s instructions. See CLIA-waived point-of-care testing.
- Moderate or high: the laboratory needs a certificate, is inspected and must meet quality system standards covering proficiency testing, quality control and quality assurance, and personnel. The CDC states that the standards for moderate and high complexity testing differ only in the personnel requirements. See high-complexity testing requirements.
- Provider-performed microscopy: a separate certificate for a limited list of microscopy procedures performed by physicians, dentists or midlevel practitioners, as the CDC describes.
CMS summarizes the logic: the more complicated the test, the more stringent the requirements. The database is therefore the first step in deciding whether a planned assay can be run under the certificate a laboratory already holds.
A worked workflow for a laboratory evaluating a new assay
This sequence is editorial, built from the steps the official pages describe. First, identify the test system by manufacturer and analyte in the FDA CLIA Database and note its complexity and effective date. Second, if it is waived, confirm the laboratory holds a CLIA certificate that covers waived testing and that staff follow the manufacturer’s instructions exactly, since the CDC ties waived status to those instructions. Third, if it is moderate or high, check the laboratory’s certificate type and status on the CMS QCOR lookup and plan for proficiency testing, quality control, quality assurance and the personnel the category requires. Fourth, if the test is a laboratory-developed or modified version of a categorized test, plan on the high complexity default. Fifth, if no record can be found, ask the manufacturer for its CLIA Record number rather than assuming a category, because an uncategorized system defaults to high complexity.
Typical timeline phases for a categorization
These are the FDA’s stated targets from its categorization page on 2026-11-19, not guarantees: an email acknowledgment within one week of receiving the submission; for a concurrent CR, notification within two weeks of the final decision on the parent marketing submission; for a standalone CR, notification within 30 days of receipt. After that comes the weekly database update. A laboratory planning a new assay should therefore expect a gap between a manufacturer’s clearance and the public listing, and ask the manufacturer for its CR number.
Common mistakes
- Searching the FDA database for a laboratory. It lists tests. Use the CMS QCOR lookup for laboratories.
- Treating FDA clearance as CLIA categorization. Clearance of a device and its CLIA complexity are separate determinations, even though a concurrent CR is created alongside the marketing submission.
- Assuming a modified test keeps its category. The CDC states that laboratory-developed or modified tests default to high complexity.
- Typing long phrases. The search page warns that too many words or misspellings may return no results.
- Waiting for a paper certificate. CMS no longer mails paper certificates or fee coupons.
The related databases at a glance
The data table below separates the FDA CLIA Database from the other sources people confuse with it. For a broader comparison of laboratory quality frameworks, see ISO 15189 vs CLIA.
Frequently asked questions
How to print a CLIA certificate?
CMS no longer mails paper certificates or fee coupons; certificates are delivered electronically, and the CMS CLIA page directs laboratories to the QCOR system to access their certificate. The laboratory can check its certification and survey status at any time on the free QCOR CLIA Laboratory Lookup. Questions about status or upgrades go to the laboratory’s State Survey Agency. The FDA CLIA Database does not hold certificates.
How do laboratories ensure the accuracy and reliability of test results?
CLIA’s stated objective is to ensure quality laboratory testing. In practice, laboratories running waived tests follow the manufacturer’s instructions under a CLIA certificate, while laboratories running moderate or high complexity tests are inspected and must meet quality system standards including proficiency testing, quality control, quality assurance and personnel requirements, per the CDC. The test’s complexity category in the FDA database tells a laboratory which track applies.
What is a CLIA approved?
“CLIA approved” is informal wording that mixes two things. A laboratory is certified under CLIA by CMS and its State Survey Agency, and a test system is categorized as waived, moderate or high complexity by the FDA. The FDA clears or approves the device through a separate premarket pathway. The FDA CLIA Database shows the categorization of a test system only.
Does the FDA certify labs?
No. The FDA categorizes test systems by complexity and handles CLIA waiver applications. Laboratory certification, fees and surveys are handled by CMS and the State Survey Agencies, which are authorized to set and enforce CLIA standards, and CMS states that official CLIA communications come only from CMS or the State Survey Agency.
Sources
- FDA: CLIA Database search, checked 2026-11-19
- FDA: CLIA Categorizations, checked 2026-11-19
- FDA: CLIA Waiver by Application Decision Summaries, checked 2026-11-19
- CDC: CLIA Test Complexities, checked 2026-11-19
- CMS: Clinical Laboratory Improvement Amendments (CLIA), checked 2026-11-19
Data: Where to look for CLIA information: FDA CLIA Database compared with related CLIA sources
Compares what each public CLIA resource describes (test systems or laboratories), who publishes it, how it is searched and how it is updated, compiled from the FDA, CMS and CDC pages read on 2026-11-19.
Period covered: 2026. Coverage: United States.
| Resource | Publisher | What a record describes | How it is searched | Update note |
|---|---|---|---|---|
| FDA CLIA Database | FDA (CDRH) | A categorized test system and its complexity (waived, moderate or high) | Test system or manufacturer, analyte, document number, complexity, analyte specialty, 510(k) exempt, effective date | Updated weekly with new categorizations |
| QCOR CLIA Laboratory Lookup | CMS | A laboratory's certification and survey status | Laboratory | Free to use at any time |
| CLIA Waiver by Application decision summaries | FDA (CDRH) | The FDA's decision on a manufacturer's request to categorize a moderate-complexity test as waived | Published decision summaries | Published since 2017 |
| CLIA test complexities page | CDC | Explains waived, moderate and high categories and which agency does what | Not a database | Explanatory page |
Sources
- FDA: CLIA Database search (accessed 2026-11-19)
- FDA: CLIA Categorizations (accessed 2026-11-19)
- FDA: CLIA Waiver by Application Decision Summaries (accessed 2026-11-19)
- CDC: CLIA Test Complexities (accessed 2026-11-19)
- CMS: Clinical Laboratory Improvement Amendments (CLIA) (accessed 2026-11-19)
Compiled by CASRAI from the sources above. Free to reuse under CC BY 4.0 with attribution.







